Catechin multimers as therapeutic drug delivery agents
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/35
A61K-031/19
출원번호
US-0137368
(2002-05-03)
발명자
/ 주소
Larson, Drake
대리인 / 주소
Smith, Chalin A.Smith Patent Consulting
인용정보
피인용 횟수 :
5인용 특허 :
10
초록▼
Described herein are catechin multimers, and particularly substituted catechin multimers, and their use as carrier moieties for the delivery of nucleophilic and cationic bioactive therapeutic agents to target sites in vivo. For example, substituted catechin multimers of the present invention may be
Described herein are catechin multimers, and particularly substituted catechin multimers, and their use as carrier moieties for the delivery of nucleophilic and cationic bioactive therapeutic agents to target sites in vivo. For example, substituted catechin multimers of the present invention may be administered alone, for the treatment of stenotic vascular diseases and disorders, such as atherosclerosis (also known as arteriosclerosis) and coronary heart disease (also known as coronary artery disease and ischemic heart disease). Alternatively, catechin multimers, substituted and otherwise, may be complexed with nucleophilic and/or cationic bioactive therapeutic agents, such as anti-thrombotic agents, cholesterol lowering agents, anti-plaque agents, anti-cancer agents, chemotherapeutic agents, anti-inflammatory agents, antibiotics, antimicrobials, wound healing agents, and the like, for the treatment of a variety of diseases and disorders, including but not limited to cardiac and vascular stenoses, cancer, inflammatory conditions, neurological conditions, infection, wounds, burns and the like. The catechin multimers, particularly the substituted catechin multimers, described herein have a strong affinity for polar proteins residing in the vascular endothelium as well as cell walls and membranes, and, accordingly, are able to provide targeted delivery of bioactive agents embedded therein and/or complexed therewith so as to potentiate their therapeutic effects. The therapeutic complexes may be pharmaceutically formulated "neat" (e.g., without additives) or with additives such as pharmaceutical carriers, diluents, buffers, adjuvants, excipients, surfactants, and stabilizers.
대표청구항▼
Described herein are catechin multimers, and particularly substituted catechin multimers, and their use as carrier moieties for the delivery of nucleophilic and cationic bioactive therapeutic agents to target sites in vivo. For example, substituted catechin multimers of the present invention may be
Described herein are catechin multimers, and particularly substituted catechin multimers, and their use as carrier moieties for the delivery of nucleophilic and cationic bioactive therapeutic agents to target sites in vivo. For example, substituted catechin multimers of the present invention may be administered alone, for the treatment of stenotic vascular diseases and disorders, such as atherosclerosis (also known as arteriosclerosis) and coronary heart disease (also known as coronary artery disease and ischemic heart disease). Alternatively, catechin multimers, substituted and otherwise, may be complexed with nucleophilic and/or cationic bioactive therapeutic agents, such as anti-thrombotic agents, cholesterol lowering agents, anti-plaque agents, anti-cancer agents, chemotherapeutic agents, anti-inflammatory agents, antibiotics, antimicrobials, wound healing agents, and the like, for the treatment of a variety of diseases and disorders, including but not limited to cardiac and vascular stenoses, cancer, inflammatory conditions, neurological conditions, infection, wounds, burns and the like. The catechin multimers, particularly the substituted catechin multimers, described herein have a strong affinity for polar proteins residing in the vascular endothelium as well as cell walls and membranes, and, accordingly, are able to provide targeted delivery of bioactive agents embedded therein and/or complexed therewith so as to potentiate their therapeutic effects. The therapeutic complexes may be pharmaceutically formulated "neat" (e.g., without additives) or with additives such as pharmaceutical carriers, diluents, buffers, adjuvants, excipients, surfactants, and stabilizers. llustrated, for example, a process for the preparation of toner comprising (i) aggregating with a metal complex, or metal ion a colorant dispersion with a latex emulsion and optional additives to form aggregates; (ii) coalescing or fusing the aggregates; and optionally (iii) isolating, washing, and drying the toner. Illustrated in U.S. Pat. No. 5,994,020, the disclosure of which is totally incorporated herein by reference, are toner preparation processes, and more specifically, a process for the preparation of toner comprising: (i) preparing, or providing a colorant dispersion; (ii) preparing, or providing a functionalized wax dispersion comprised of a functionalized wax contained in a dispersant mixture comprised of a nonionic surfactant, an ionic surfactant, or mixtures thereof; (iii) shearing the resulting mixture of the functionalized wax dispersion (ii) and the colorant dispersion (i) with a latex or emulsion blend comprised of resin contained in a mixture of an anionic surfactant and a nonionic surfactant; (iv) heating the resulting sheared blend of (iii) below about the glass transition temperature (Tg) of the resin particles; (v) optionally adding additional anionic surfactant to the resulting aggregated suspension of (iv) to prevent, or minimize additional particle growth of the resulting electrostatically bound toner size aggregates during coalescence (iv); (vi) heating the resulting mixture of (v) above about the Tg of the resin; and optionally, (vii) separating the toner particles; and a process for the preparation of toner comprising blending a latex emulsion containing resin, colorant, and a polymeric additive; adding an acid to achieve a pH of about 2 to about 4 for the resulting mixture; heating at a temperature about equal to, or about below the glass transition temperature (Tg) of the latex resin; optionally adding an ionic surfactant stabilizer; heating at a temperature about equal to, or about above about the Tg of the latex resin; and optionally cooling, isolating, washing, and drying the toner. Illustrated in U.S. Pat. No. 5,688,626, the disclosure of which is totally incorporated herein by reference, are toner processes, and more specifically, a process for the preparation of toner in which the ionic surfactant selected for the preparation of the latex particles is an anionic surfactant and wherein the pigment dispersion selected contains a nonionic surfactant and optionally an anionic surfactant to which a cationic surfactant solution is added to form aggregates of a toner size followed by the addition of an anionic surfactant to stabilize the aggregates, followed by heating the resulting mixture during the coalescence step to a temperature above the resin Tg, to provide toner composite. Illustrated in U.S. Pat. No. 6,132,924, the disclosure of which is totally incorporated herein by reference, are toner processes, and more specifically, a process for the preparation of toner wherein a dual coagulant or flocculating mixture such as a metal halide and a cationic surfactant solution is added to form toner aggregates, followe
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (10)
DeLuca Hector F. (Madison WI) Schnoes Heinrich K. (Madison WI) Ikekawa Nobuo (Tokyo WI JPX) Tanaka Yoko (Madison WI) Kobayashi Yoshiro (Tokyo JPX), 24,24-Difluoro-1a
상세보기
Drake Larson, Compositions for reducing vascular plaque formation and methods of using same.
Bombardelli Ezio (Milan ITX) Morazzoni Paolo (Milan ITX), Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to.
Ahn Hee-Yul,KRX ; Park Jong-Bum,KRX ; Yun Yeo-Pyo,KRX ; Cho Myeong-Chan,KRX ; Kim Young-Gyu,KRX, Method for preventing or treating coronary restenosis with catechin.
Gould Michael N. (Madison WI) Crowell Pamela L. (Indianapolis IN) Elson Charles E. (Madison WI) Ren Zhibin (Madison WI), Uses of perillic acid methyl ester.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.